Sakamoto Kathleen M
Division of Hematology-Oncology, Mattel Children's Hospital, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1752, USA.
Curr Opin Investig Drugs. 2004 Dec;5(12):1329-39.
SUGEN is developing SU-11248, an orally active inhibitor of platelet-derived growth factor tyrosine kinase (TK) and other TK signaling pathways, as a potential anticancer agent. By October 2003, phase III trials for gastrointestinal stromal tumors and renal cell carcinoma were underway.
SUGEN公司正在研发SU-11248，一种口服活性血小板衍生生长因子酪氨酸激酶（TK）及其他TK信号通路抑制剂，作为一种潜在的抗癌药物。截至2003年10月，针对胃肠道间质瘤和肾细胞癌的III期试验正在进行中。
Zotero 插件